Thermo Obtains Exclusive License for ETD Technology from the University of Virginia
News Apr 06, 2006
Thermo Electron Corporation has concluded a licensing agreement with the University of Virginia for Electron Transfer Dissociation (ETD), an ion fragmentation technology that provides sequence information not available from conventional methods currently in use on ion trap mass spectrometers.
Ken Miller, product marketing manager for Proteomics at Thermo, stated, "ETD is an application that benefits immensely from the large ion storage capacity and fast cycle time of Thermo’s Finnigan™ LTQ™ linear ion trap mass spectrometer. As a result, we fully expect ETD to be available for this instrument before the end of 2006.”
According to Miller, the power of ETD on the Finnigan LTQ has already been demonstrated for:
1) Mapping of post-translational modification (PTM) sites, particularly phosphorylation, 2) Allowing more comprehensive proteomic sample profiling than with collision-induced dissociation (CID) alone
3) Fragmenting and analyzing large peptide fragments as well as intact proteins.
“ETD will help shed new light on many important, unanswered questions in contemporary biology,” said Dr. Don Hunt, principal investigator at the University of Virginia. “ETD represents a landmark advance in the field of proteomics. This new methodology is a powerful and reliable analytical solution for protein characterization.”
Dr. Hunt has used ETD to characterize the biochemical basis of histone protein action in the regulation of DNA transcription. Additionally, he has shown that the pattern of histone phosphorylation, methylation and acetylation is critical to DNA expression. “These studies would not have been possible without ETD,” added Hunt.
“Thermo has been working closely for several years with Dr. Hunt’s laboratory on the development of ETD, and we are pleased to be licensing it from the University of Virginia,” said Iain Mylchreest, vice president and general manager, Life Sciences Mass Spectrometry at Thermo Electron Corporation.
“This clearly demonstrates Thermo’s commitment to acquiring innovative new technologies and developing integrated solutions that address the research and analytical challenges facing the proteomics community.“
BioAscent Establishes Integrated Drug Discovery Services OfferingNews
Dr Phil Jones to join as new CSO to lead company’s extended capabilities in medicinal chemistry and in vitro biosciences.READ MORE
Lab Innovations returns to the NEC, Bimingham , UKNews
Save the date for the UK’s only lab-dedicated exhibition showcase!READ MORE
A Breath Test for Early Diagnosis of Oesophageal and Gastric CancerNews
In a multi-centre clinical trial of 335 patients, a new breath test can identify oesophageal and gastric cancer from benign diseases with 85 per cent accuracy. Unlike other methods, the test is non-invasive.READ MORE
Comments | 0 ADD COMMENT
International Conference on Biobetters and Regulatory Affairs
Jun 27 - Jun 28, 2018
9th International Conference on Mass Spectrometry and Chromatography
Sep 21 - Sep 22, 2018